Oxygen Biotherapeutics, Inc. Establishes Warfighter Division

Hires Army Veteran to Lead It

COSTA MESA, Calif., March 24 /PRNewswire-FirstCall/ -- Oxygen Biotherapeutics,
Inc. (OTC Bulletin Board: OXBO) today announced it has hired Army Reserve
officer Kirk Harrington, a Special Operations Force field-grade officer,
diplomat, and government advisor as head of its newly-established warfighter
division.

Harrington is an 18-year army veteran who in 2006 was appointed by the United
States Department of State as a senior adviser to the Government of Iraq. As
the sole diplomat to the Iraqi Ministries of Transportation and Construction
and Housing, he oversaw every facet of Iraqi reconstruction efforts to include
new implementation of roads and bridges, ports, airfields and railroads. His
background includes lecturing on Middle Eastern affairs at the US Military
Academy, West Point and he is a founding member of Emerging Foreign Market
Collaboration, LLC., a New York-based government consulting firm.

The new warfighter division is a result of the Purple Heart Injury Laboratory
(PHIL) initiative between the company and Virginia Commonwealth University
announced last month to establish a federal defense appropriation-funded joint
venture focusing on developing new treatments for military battlefield
injuries. PHIL will be jointly managed and operated research laboratories
focusing on healing battlefield injuries with new therapies and concepts.

"Kirk's role will be to connect the company with military research efforts and
help us with sources of government funding for the military-related
applications of Oxycyte(R) such as blast-related TBI, decompression sickness,
and wound treatment. It's my expectation that Kirk's efforts will be more than
self-supporting and that this division will become an important revenue
generator for the company," said Chris J. Stern, company chairman and CEO. "He
has outstanding contacts in the Department of Defense and other parts of the
federal government along with a disciplined approach to getting things done.
I'm looking forward to Kirk putting those assets to work in helping the
company with its product development plans."

"I know only too well about the devastating effects of blast-related TBI and
other wounds suffered by our military personnel. I believe Oxycyte can help
them have a better and faster recovery and I want to help make it available as
fast as possible. I'm excited about being a part of this with Oxygen
Biotherapeutics," said Harrington.

About Oxygen Biotherapeutics, Inc.
Oxygen Biotherapeutics, Inc. is dedicated to commercializing innovative
pharmaceuticals and medical devices in the field of oxygen therapeutics and
continuous substrate monitoring. The company has under development a
perfluorocarbon therapeutic oxygen carrier and liquid ventilation product
(Oxycyte(R)) and an implantable glucose sensor. These products are based upon
core technologies that include biomedical applications for PFCs and medical
and industrial applications for biosensors. Each of the product candidates is
designed with advantages over currently marketed products in major markets
including traumatic brain injury, sickle cell crisis pain, trauma, wound care,
acute respiratory distress syndrome, stroke, myocardial infarction, surgery,
and diabetes. More information is available at www.oxybiomed.com.

Caution Regarding Forward-Looking Statements
This news release contains certain forward-looking statements by Oxygen
Biotherapeutics, Inc. that involve risks and uncertainties and reflect the
company's judgment as of the date of this release. These statements include
those referring to the expectations for the company's new Warfighter Division
and the role of the employee hired to lead it. Actual events or results may
differ from Oxygen Biotherapeutics, Inc.'s expectations. There can be no
assurance that the new employee will have any success in generating funding
for the company from any U. S. Government source, that the new division will
be financially self-supporting, or that it will generate any meaningful
revenue for the company. Additional information concerning these and other
risk factors affecting Oxygen Biotherapeutics, Inc.'s business can be found in
the company's public periodic filings with the Securities and Exchange
Commission, which are available via www.oxybiomed.com. Oxygen Biotherapeutics,
Inc. disclaims any intent or obligation to update these forward-looking
statements beyond the date of this release. This caution is made under the
safe harbor provisions of the Private Securities Litigation Reform Act of
1995.

SOURCE Oxygen Biotherapeutics, Inc.

Abe Wischnia of Abe Wischnia & Associates, +1-619-795-2345